AlzeCure publishes its interim report for January – September 2020
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – September 2020 is now available on the company’s website: https://www.alzecurepharma.se/en/section/investors/financial-reports/“AlzeCure has had another productive quarter during which its operations progressed according to plan, with advances in all three of our project platforms: NeuroRestore, Alzstatin and Painless. Preparations to begin two additional clinical trials at the end of the year for the drug candidates ACD856 and ACD440 are proceeding according to plan.” Martin